# Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
Canonical URL: https://biopharmsignal.com/news/VYGR/voyager-to-present-at-h-c-wainwright-7th-annual-neuro-perspectives-hybrid-confer-3d59c3bb
Ticker: VYGR
Company: Voyager Therapeutics
Source: Voyager Therapeutics
Published: 2026-06-11 20:01 EST
## Summary

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics...

## Article Body
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, will participate in a pre-recorded fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference.

An on-demand webcast of the pre-recorded fireside chat will be available and may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com starting at 7:00 a.m. ET on June 15, 2026. The on-demand webcast will be archived on the Company’s website for at least 30 days.

About Voyager Therapeutics Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit http://www.voyagertherapeutics.com .

Voyager Therapeutics ® is a registered trademark, and TRACER™ and Voyager NeuroShuttle™ are trademarks, of Voyager Therapeutics, Inc.

Contacts Trista Morrison, NACD.DC, tmorrison@vygr.com Investors: Sarah McCabe, sarah.mccabe@altasum.com Media: Lisa Guiterman, voyagerpr@scientpr.com
## Recent Company News
- 2026-07-13 12:01 EST — [Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026](https://biopharmsignal.com/news/VYGR/voyager-demonstrates-single-iv-dose-of-vy1706-well-tolerated-reduced-tau-in-6-mo-d6b19d18) — Source: Voyager Therapeutics
- 2026-06-29 12:01 EST — [Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026](https://biopharmsignal.com/news/VYGR/voyager-s-tau-targeted-gene-therapy-vy1706-for-alzheimer-s-disease-to-be-feature-7e183bb9) — Source: Voyager Therapeutics
- 2026-06-11 20:01 EST — [Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference](https://biopharmsignal.com/news/VYGR/voyager-to-present-at-h-c-wainwright-7th-annual-neuro-perspectives-hybrid-confer-3d59c3bb) — Source: Voyager Therapeutics
- 2026-06-01 12:00 EST — [Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease](https://biopharmsignal.com/news/VYGR/voyager-receives-fda-ind-clearance-for-vy1706-first-gene-therapy-approach-to-red-9cffdbcc) — Source: Voyager Therapeutics
- 2026-05-13 10:01 EST — [Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026](https://biopharmsignal.com/news/VYGR/voyager-asgct-late-breaker-single-iv-dose-of-vy1706-well-tolerated-reduced-tau-i-daac488a) — Source: Voyager Therapeutics
## Related News
- 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a)
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)